KRN5500 is a semisynthetic derivative of the nucleoside-like antineoplastic antibiotic spicamycin, first isolated from the bacterium Streptomyces alanosinicus. KRN 5500 inhibits protein synthesis by interfering with endoplasmic reticulum and Golgi apparatus functions. This agent also induces cell differentiation and caspase-dependent apoptosis. The directory classifies it as a clinical API with a semi-synthetic source/manufacturing origin. Other names for this substance include Benzoylated spicamycin analogue and Krn 5500. Its PubChem CID is 6440176.
Krn-5500
| CAS No | 151276-95-8 |
|---|---|
| Molecular Formula | C28H43N7O7 |
| Molecular Weight | 589.70 g/mol |
| Synonyms | (2E,4E)-N-[2-[[(2R,3R,4R,5R,6S)-2-[(1S)-1,2-dihydroxyethyl]-4,5-dihydroxy-6-(7H-purin-6-ylamino)oxan-3-yl]amino]-2-oxoethyl]tetradeca-2,4-dienamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
KRN5500 is a semisynthetic derivative of the nucleoside-like antineoplastic antibiotic spicamycin, first isolated from the bacterium Streptomyces alanosinicus. KRN 5500 inhibits protein synthesis by interfering with endoplasmic reticulum and Golgi apparatus functions.
The listed CAS number is 151276-95-8.
The listed molecular formula is C28H43N7O7.
The listed molecular weight is 589.70 g/mol.
(2E,4E)-N-[2-[[(2R,3R,4R,5R,6S)-2-[(1S)-1,2-dihydroxyethyl]-4,5-dihydroxy-6-(7H-purin-6-ylamino)oxan-3-yl]amino]-2-oxoethyl]tetradeca-2,4-dienamide.
The source lists Benzoylated spicamycin analogue and Krn 5500.